Metastatic Breast Cancer Treatment Market Highlights 2020-2029
The Metastatic Breast Cancer Treatment Market is estimated to grow with a high CAGR during the forecast period, i.e., 2021-2029. The increasing prevalence of breast cancer globally, along with the growing recurrence rate of breast cancer is expected to fuel the development of this market. The growth of the market can also be attributed to factors such as the increasing geriatric population and an increase in exposure to cancer risk factors linked to social and economic development. Cancer is currently the second leading cause of death worldwide. According to the Globocan report, global cancer burden is estimated to have risen to 19.3 million cases and 10 million cancer-related deaths in 2020. According to Globocan report 2020, the incidence rate of breast cancer was 5.20% which accounted for 2.26 million new cases globally with a mortality rate of 6.9%. Such increasing prevalence of breast cancer is expected to drive the growth of global metastatic breast cancer treatment market.
The market is segmented based on treatment type into chemotherapy, radiation therapy, biologic, targeted therapy, breast surgery, and hormone therapy, out of which, chemotherapy and radiation therapy segment is anticipated to grab the largest share by the end of 2021 on account of its high level of specificity and lesser side-effects. Moreover, increasing government approval of new treatment & drugs globally is also projected to contribute to the growth of the segment during the forecast period. CLICK TO DOWNLOAD SAMPLE REPORT
Based on end-user, the hospital segment held the largest share in the global metastatic breast cancer treatment market on the back of increasing patient influx and increasing spending by the hospitals on breast cancer treatments.
Metastatic Breast Cancer Treatment Market Regional Synopsis
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the increasing breast cancer prevalence and the rising geriatric population in the region. Furthermore, in 2021, the market in North America is evaluated to occupy the largest share in terms of revenue, owing to the growing healthcare investment, accompanied by the presence of leading healthcare service providers, and the increasing prevalence of cancer in the region. Along with this, the countries in North America such as the United States is promoting campaigns for breast cancer patients, which is also expected to contribute to the market growth in the region. According to the report published by the National Cancer Institute, in 2020, 1.8 million new cancer cases were registered in the United States. Such increasing rate of cancer is further expected to drive the demand for metastatic breast cancer treatment in the North American countries. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global metastatic breast cancer treatment market on account of its proven success in terms of technology development and a high prevalence of breast cancer in the region. As per the analysis of the Globocan, 0.53 million new breast cancer cases were registered in the European Union, with 0.14 million deaths in 2020. Such growing number of deaths due to breast cancer is expected to increase the R&D activities to develop better treatment in the market.
The global metastatic breast cancer treatment market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global metastatic breast cancer treatment market include the following segments:
By Treatment Type
- Chemotherapy
- Radiation Therapy
- Biologic
- Targeted Therapy
- Breast Surgery
- Hormone Therapy
By End-user
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others
Growth Drivers
- Rising Prevalence of Breast Cancer
- Increasing Investment in R&D
Challenges
- Risk of Adverse Effects of Radiation Exposure
- Lack of Awareness
Top Featured Companies Dominating the Market
- F. Hoffmann-La Roche Ltd
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Merck & Company, Inc.
- AstraZeneca Plc.
- Novartis
- Bayer AG
- Pfizer Inc.
- Eli Lilly and Company
- Sun Pharmaceutical Industries Limited
- Johnson & Johnson
- GlaxoSmithKline plc.
